medigraphic.com
ISSN 2218-6719 (Print)

2012, Number 4

<< Back Next >>

Rev Cub de Tec de la Sal 2012; 3 (4)

Síntomas no motores en pacientes con enfermedad de Parkinson

Parada BY, Soto LA, Lara FGE, Santos SA, Hernández RTE, Mesa BY

Language: Spanish
References: 24
Page: 1-13
PDF size: 107.85 Kb.


ABSTRACT

No abstract.


REFERENCES

  1. Carod-Artala FJ, Ziomkowskia S, Moura˜o Mesquitaa H, Martınez- Martinb Behari PM. Anxiety and depression: Main determinants of health-related quality of life in Brazilian patients with Parkinson’s disease. Parkinsonism and Related Disorders 14 (2008) 102–108.

  2. Chaudhuri KR, Prieto-Jurcynska C, Naidu Y, et al. The nondeclaration of nonmotor symptoms of Parkinson's disease to health care professionals: an international study using the nonmotor symptoms questionnaire.Mov. Disord.2010;25:697-701

  3. Nausieda PA, Weiner W, Kaplan LR. Sleep disruption in the course of chronic levodopa therapy: an early feature of the levodopa psychosis. Clin Neuropharmacol 1982; 5:183–194.

  4. Chaudhuri KR, Martínez-Martín P, Schapira AH, et al. International multicenter pilot study of the first comprehensive self-completed nonmotor symptoms questionnaire for Parkinson's disease: the NMSQuest study. Mov Disord.2006; 21:916-923.

  5. Chaudhuri KR, Martínez-Martín P, Brown RG, et al.The metric properties of a novel non-motor symptoms scale for Parkinson's disease:results from an international pilot study. Mov Disorder 2007;22:1901-1911.

  6. Srivastava AK, Pandey RM. Quality of life in patients with Parkinson’s disease. Parkinsonism Relat Disord 2005; 11:221–6.

  7. Aarsland D, Brønnick K, Alves G, Tysnes OB, Pedersen KF, Ehrt U, Larsen JP.The spectrum of neuropsychiatric symptoms in patients with early untreated Parkinson’s disease. J Neurol Neurosurg Psychiatry 2009; 80: 928-930.

  8. Quelhas R, Costa M. Anxiety, Depression, and Quality of Life in Parkinson’s disease. J Neuropsychiatry Clin Neurosci 2009; 21:4.

  9. da SilvaT, Munhoz R, Alvarez C, et al. Depression in Parkinson’s disease: a double blind, randomized, placebo-controlled pilot study of omega-3 fatty-acid supplementation. J Affect Disod.2008; 111:351-359.

  10. Menza M, Dobkin R, Marin H, et al. A controlled trial of antidepressants in patients with Parkinson disease and depression.Neurology.2009; 72:886-892.

  11. Barone P, Poewe W, Albrecht S, et al. Pramipexole for the treatment of depressive symptoms in patients with Parkinson’s disease: a randomised, double- blind, placebo-controlled trial. Lancet Neurol.2010;9:573-580

  12. Muzerengia S , Contrafattoc D, Ray Chaudhuria K. Non-motor symptoms: Identification and management. Parkinsonism and Related Disorders 2007; 13:S450–S456.

  13. Isella V, Iurlaro S , Piolti R, Ferrarese C, Frattola L, Appollonio I. Physical anhedonia in Parkinson’s disease .J Neurol Neurosurg Psychiatry 2003;74:1308–1311.

  14. Postuma RB, Gagnon JF, Vendette M, Charland K, Montplaisir J . REM sleep behaviour disorder in Parkinson’s disease is associated with specific motor features .J Neurol Neurosurg Psychiatry 2008; 79: 1117- 1121.

  15. van Hilten JJ, Weggeman M, Van der Velde EA, Kerkhof GA, van Dijk JG, Roos RAC. Sleep, excessive daytime sleepiness and fatigue in Parkinson’s disease. J Neural Transm [P-D Sect] 1993; 5: 235–244.

  16. Pal PK, Calne S, Samii A, Fleming JAE. A review of normal sleep and its disturbances in Parkinson’s disease .Parkinsonism and Related Disorders 1999; 5:1–17.

  17. Fernandez HH, Okun MS, Rodríguez RL, et al. Quetiapine improves visual hallucinations in Parkinson disease but not through normalization of sleep architecture: results from a double-blind clinicalpolysomnography study.Int J Neurosci.2009:119:2196-2205.

  18. Menza M, Dobkin R, Marin H, et al. Treatment of insomnia in Parkinson’s disease:a controlled trial of eszopiclone and placebo. Mov Disord.2010; 25:1708-1714.

  19. Buscemy N, Vandermeer B, Hooton N, et al. The efficacy and safety of exogenous melatonin for primary sleep disorders. A meta-analisys.J Gen Intern Med.2005;20:1151-1158.

  20. Lee MA, Walker RW, Hildreth TJ, Prentice WM. A survey of pain in idiopathic Parkinson’s disease. J Pain Symptom Manage 2006; 32:462−9.

  21. Savica R, Rocca WA, Ahlskog JE. When Does Parkinson Disease Start? Arch Neurol 2010; 67(7):798-801.

  22. Alonso A, Garcıa Rodriguez LA, Logroscino G, Hernán MA. Use of antidepressants and the risk of Parkinson’s disease: a prospective study. J Neurol Neurosurg Psychiatry. 2009; 80(6):671-674.

  23. Shiba M, Bower JH, Maraganore DM, et al. Anxiety disorders and depressive disorders preceding Parkinson’s disease: a case-control study. Mov Disord. 2000; 15(4):669-677.

  24. . Behari M, Srivastava AK, Das RR, Pandey RM. Risk factors of Parkinson’s disease in Indian patients. J Neurol Sci. 2001; 190(1-2):49- 55.




2020     |     www.medigraphic.com